Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2873-2878

  Garrido, Carolina ^a   Villacian, Jorge ^b   Zahonero, Natalia ^a   Pattery, Theresa ^b   Garcia, Federico ^c   Gutierrez, Felix ^d   Caballero, Estrella ^e   Van Houtte, Margriet ^b   Soriano, Vincent ^a   De Mendoza, Carmen ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Virco BVBA   (Belgium)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d Hospital General Universitario   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS RESISTANCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; PYRROLIDINONES; QUINOLONES;

EID: 84861136225     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06170-11     Document Type: Article

References (22)

1. Ceccherini-Silberstein F, et al. 2010. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J. Antimicrob. Chemother. 65:2305-2318.
2. Cooper DA, et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
3. DeGruttola V, et al. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5:41-48. (Pubitemid 30261205)
4. DeJesus E, et al. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment- naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5. (Pubitemid 44306480)
5. Delelis O, et al. 2010. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob. Agents Chemother. 54:491-501.
6. Garrido C, et al. 2012. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res. Hum. Retroviruses 28:156-164.
7. Garrido C, et al. 2010. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J. Antimicrob. Chemother. 65:320-326.
8. Hazuda D, et al. 2007. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with tripleclass resistant HIV-1 infection. Antivir. Ther. 12(Suppl 1):10.
9. Hightower KE, et al. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55:4552-4559.
10. Jones G, et al. 2007. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor GS-9137 (JTK-303), abstr 627. Abstr. 14th Conf. Retrovirus Opportun. Infect., Los Angeles, CA, 25 to 28 February 2007.
11. Lennox JL, et al. 2010. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, sub-group, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 55:39-48.
12. Martinez-Cajas J, Wainberg M. 2007. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 76:203-221. (Pubitemid 47603256)
13. McColl D, et al. 2007. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antivir. Ther. 12(Suppl 1):S11.
14. Métifiot M, et al. 2011. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 25:1175-1178.
15. Miller M, et al. 2008. Longitudinal analysis of resistance to the HIV-1 integrase inhibitor RAL: results from P005 a phase II study in treatment experienced patients. Antivir. Ther. 13(Suppl 3):A8.
16. Miller V, Larder B. 2001. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir. Ther. 6(Suppl 3):25-44. (Pubitemid 32938761)
17. Pérez Cachafeiro S, et al. 2009. Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin. Infect. Dis. 48:1467-1470.
18. Reigadas S, et al. 2010. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions. PLoS One 5:e10311.
19. Steigbigel RT, et al. 2010. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin. Infect. Dis. 50:605-612.
20. Van Baelen K, et al. 2009. A combined genotypic and phenotypic HIV type 1 recombinant virus assay for the reverse transcriptase and integrase genes. J. Virol. Methods 161:231-239.
21. Van Hal S, et al. 2009. HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology 6:12.
22. Verlinden Y, et al. 2005. Assessment of the Antivirogram performance over time, including a revised definition of biological test cut-off values. Antivir. Ther. 10(Suppl):S51.